Endometrial carcinoma cell line originiating from simple epithelial cells. Positive for both estrogen receptor isoforms and progesterone receptor B, presents mutations in PTEN and K-Ras genes, one tumor suppressor and one oncogene frequently mutated in endometrial cancers. Cell line expresses high levels of MMP-2 , no MMP-9 and weak expression of TIMP-2. Cells have weak levels of phosphorylated Akt adn sow sensitivity to drugs commonly used in chemotherapy. Very aggressive cell line with high invasiveness in vitro Useful for studying mechanisms involved in the invasion of endometrial cancer cells and their regulation by sex steroids.
CRISPR:
No
Production details:
Tumor was minced with scisors into OSE without FBS. Enzymatic dissociation was done and the cellular fraction was diluted 1:5 in OSE media with 10% FBS in 37C in 5%CO2 for 24-28 hours. After cells were able to adhere, they were washed with PBS and passaged with OSE + 10% FBS until cell line was established. Afterwards, cells were grown and maintained in DMEM-F12 with HEPES (4-(4-hydroxyethyl)-1-piperazineethanesulfonic acid) adn teh medium was supplemented with 10&v/v bovine growth serum (BGS) and 50ug/ml gentamycin.
Cellosaurus ID:
CVCL_A423
Disease:
Cancer
Cat. #:
161896
Cancer types:
Ovarian cancer
Research Fields:
Cancer
Organism:
Human
Tissue:
Ovary
Morphology:
Small polygonal cells organized in pavement-like arrangement
Growth properties:
Mixed
Primary citation:
Dery et al. 2007. Reproductive Biology and Endocrinology. 25,5:(38). PMID 17894888
Format:
Frozen
Storage conditions:
Liquid Nitrogen
Shipping conditions:
Dry Ice
Growth medium:
Grown and maintained in DMEM-F12 with HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) supplemented with 10% v/v bovine growth serum (BGS) and 50 ug/ml gentamycin. For experimentation without steroid hormones, cell line cultured 2 weeks minimum in phenol-free DMEM-F12 supplemented with 10% v/v dextran-charcol stripped FBS and 50ug/ml gentamycin.
Temperature:
37° C
Atmosphere:
5% CO2
Biosafety level:
1
References:
Fabi, et al. 2021. Mol Oncol. 15(8):2106-2119. PMID: 33338300
Aslan, et al. 2018. BMC Cancer. 9,18(1):168. PMID: 29426295
Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.